Latest news
25 items- SECSEC Form 6-K filed by I-MAB6-K - NovaBridge Biosciences (0001778016) (Filer)
- SECSEC Form 6-K filed by I-MAB6-K - NovaBridge Biosciences (0001778016) (Filer)
- SECSEC Form 6-K filed by I-MAB6-K - NovaBridge Biosciences (0001778016) (Filer)
- PRI-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech PlatformNew corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwideStrategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DMECompany core asset, g
- SECSEC Form 6-K filed by I-MAB6-K - I-Mab (0001778016) (Filer)
- SECSEC Form 6-K filed by I-MAB6-K - I-Mab (0001778016) (Filer)
- SECSEC Form 6-K filed by I-MAB6-K - I-Mab (0001778016) (Filer)
- SECAmendment: SEC Form 6-K/A filed by I-MAB6-K/A - I-Mab (0001778016) (Filer)
- SECSEC Form 6-K filed by I-MAB6-K - I-Mab (0001778016) (Filer)
- SECSEC Form 6-K filed by I-MAB6-K - I-Mab (0001778016) (Filer)
- PRI-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose range from 5 mg/kg Q2W up to 18 mg/kg Q3WNo differences in efficacy were observed across different CLDN18.2 expression levels, with favorable overall safetyData anchor combination clinical strategy in first line (1L) gastric cancer, a $2B potential market1Confirming Q1 2026 plans to report topline Phase 1b dose expansion combination data and initiate a global randomized Phase 2 studyData slated for "Short Talk" presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and C
- SECSEC Form 6-K filed by I-MAB6-K - I-Mab (0001778016) (Filer)
- PRI-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge BiosciencesNew business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwideIntention to pursue a Hong Kong initial public offering (IPO) to expand access to global capital and innovation through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX)Name change to be effective following shareholder approval, which is expected at the Extraordinary General Meeting (EGM) on October 24, 2025Pending acquisition of AM712 (also known as ASKG712), to be named VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, and a more potent molecule that could
- PRCellular Immunotherapy Breakthroughs Fuel $370 Billion Market SurgeEquity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- Eight new oncology approvals between July and September 2025 marked a pivotal quarter for cancer treatment[1], as cellular immunotherapy platforms continue redefining treatment paradigms for hematologic malignancies and expanding into solid tumors[2]. Recent innovations including CAR-NK cells, CAR-Treg cells, and in vivo CAR-T approaches are solving manufacturing challenges[3] while outpatient CAR-T centers now deliver advanced therapies that previously required lengthy hospital stays[4]. Alternative drug delivery methods and targeted therapy approvals for lung cancer, breast ca
- PRI-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics ConferenceThe AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract related to updated data from the Phase 1 study of givastomig as a monotherapy in heavily pre-treated patients with gastroesophageal carcinoma (GEC) has been accepted as a "short-talk" at the AACR-NCI-EORTC conference which will be held October 22-26 in Boston, Massachusetts. "As we follow patients in the ful
- PRNovel Cancer Platforms Converge as Clinical Data Reshapes Treatment ParadigmsEquity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are unveiling pivotal survival data[2] and late-breaking lung cancer[3] results that demonstrate how diverse mechanisms are succeeding where traditional approaches stalled, while regulatory agencies issued multiple September approvals spanning gene therapies, bispecifics, and novel delivery systems[4]. The momentum reflects a fundamental shift as researchers discovered how cancer hijacks immune pathways to evade attack, spurring develop
- SECSEC Form 6-K filed by I-MAB6-K - I-Mab (0001778016) (Filer)
- ANALYSTLeerink Partners initiated coverage on I-Mab with a new price targetLeerink Partners initiated coverage of I-Mab with a rating of Outperform and set a new price target of $9.00
- SECSEC Form 6-K filed by I-MAB6-K - I-Mab (0001778016) (Filer)
- SECSEC Form S-8 filed by I-MABS-8 - I-Mab (0001778016) (Filer)
- ANALYSTBTIG Research initiated coverage on I-Mab with a new price targetBTIG Research initiated coverage of I-Mab with a rating of Buy and set a new price target of $7.00
- PRI-Mab Announces Acceleration of Givastomig Investment and Leadership AppointmentsExpands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to followReiterates expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026Plans to broaden the 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC)Mr. Wei Fu, I-Mab's Chairman of the Board of Directors, appointed as Executive Chairman, supported by further executive additions ROCKVILLE, Md., Sept. 08, 2025 (GLOBE N
- SECSEC Form 6-K filed by I-MAB6-K - I-Mab (0001778016) (Filer)
- SECSEC Form 6-K filed by I-MAB6-K - I-Mab (0001778016) (Filer)
- PRI-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development CommitteeDr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of DirectorsResearch and Development Committee established to accelerate innovation and long-term growthDr. Ken Takeshita appointed to the Scientific Advisory Board ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board of Directors (the Board), effective as of August 22, 2025 and reiterated the appointment of independent director Dr. Sean Cao to the Board as of
IMAB FAQ
7 questionsWhat does I-MAB do?
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed...Where does IMAB stock trade?
I-MAB (IMAB) is listed on NASDAQ.What sector and industry is IMAB in?
I-MAB operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did I-MAB go public?
I-MAB (IMAB) completed its IPO in 2020.What are analysts saying about IMAB?
I-MAB has had 5 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $900.00 price target on 2025-10-03. Recent price targets range from $700.00 to $900.00.What companies are similar to IMAB?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IMAB side-by-side with any of them on Quantisnow.How can I track IMAB on Quantisnow?
Quantisnow aggregates I-MAB's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMAB to receive live email and push alerts on every new disclosure.